FIND A PROVIDER

XEOMIN® is available only through licensed physicians.

We think finding one should be easy. Simply enter your zip code below.

COMPARABLE PERFORMANCE


Xeomin demonstrated comparable to Botox Cosmetic

vidthumb-hcp-product_vid1

A prospective, multicenter, randomized, double blinded, parallel trial, XEOMIN® and BOTOX® subjects were randomized 1:1. The study enrolled 250 healthy female patients (≥18 years old) with glabellar lines of at least moderate severity at maximum frown. 122 subjects were treated with 20 Units of XEOMIN; 128 subjects were treated with 20 Units of BOTOX in a single treatment cycle. Patients were classified as responders only. If they had a ≥ 1 point improvement from the baseline on the Facial Wrinkle Scale (FWS) at maximum frown, as assessed by the independent review panel using subject photographs at one month post treatment.1-3

CLINICALLY PROVEN



In two randomized, double blinded, multicenter, clinical trials, Xeomin was clinically proven to temporarily improve the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.1-3

vidthumb-hcp-product_vid1

1. XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use. Prescribing Information. Merz Pharmaceuticals, LLC, 2015. 2. Carruthers A, Carruthers J, Heinz M, et al. Multicentre, randomized phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg 2013;39:551–558. 3. Hanke CW, Narins RS, Brandt F, et al. A Randomized, Placebo-Controlled, Double-Blind Phase III Trial Investigating the Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines Using a Stringent Composite Endpoint. Dermatol Surg. 2013;39(6):891-899. 4. Botox® Cosmetic (onabotulinumtoxinA) for injection. Prescribing Information. Allergan, Inc. 2016. 5. Dysport® (abobotulinumtoxinA). Prescribing Information. Medicis Pharmaceutical Corporation. 2015. 6. Bigalke H. Properties of pharmaceutical products of botulinum neurotoxins. In: Jankovic botulinum toxin therapeutic and clinical practice and science. Saunders Elsevier 2009. 7. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers’ product summaries. J Clin Pharm and Therapeutics. 2007;32:387-402. 8. Aoki KR. Preclinical update on Botox® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol.1999;6:S3-S10. 9. Frevert J. Content of botulinum neurotoxin in Botox®/Vistabel®/Dysport®/Azzalure®, and XEOMIN®/Bocouture®. Drug R D. 2010;10:67-73. 10. Kane MA, et al. (2015). Dermatol Surg 41(11):1319.

INDICATIONS AND USAGE
XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines with corrugator and/or procerus muscle activity in adult patients.
IMPORTANT SAFETY INFORMATION
WARNING: DISTANT SPREAD OF TOXIN EFFECT
See full prescribing information for complete BOXED WARNING.

 
The effects of XEOMIN® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.

CONTRAINDICATIONS
  • Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of XEOMIN should be discontinued and appropriate medical therapy immediately instituted. XEOMIN is contraindicated in patients with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.
  • Use in patients with an infection at the injection site could lead to severe local or disseminated infection. XEOMIN is contraindicated in the presence of infection at the proposed injection site(s).
WARNINGS AND PRECAUTIONS
  • The potency units of XEOMIN® are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN® cannot be compared to or converted into Units of any other botulinum toxin products.
  • Treatment with XEOMIN ® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia [See BOXED WARNING].
  • • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN®.
  • Glabellar Lines: Do not exceed the recommended dosage and frequency of administration of XEOMIN®. In order to reduce the complication of ptosis the following steps should be taken:
    • avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes;
    • corrugator injections should be placed at least 1 cm above the bony supraorbital ridge.
  • XEOMIN® contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and Creutzfeldt-Jakob disease (CJD). No cases of transmission of viral diseases or CJD have ever been reported for albumin.
ADVERSE REACTIONS
Glabellar Lines: The most commonly observed adverse reaction (incidence ≥ 2% of patients and greater than placebo) for XEOMIN® was Headache (5.4%).
DRUG INTERACTIONS
Co-administration of XEOMIN® and aminoglycoside antibiotics or other agents interfering with neuromuscular transmission, e.g., tubocurarine-type muscle relaxants, should only be performed with caution as these agents may potentiate the effect of the toxin.
Use of anticholinergic drugs after administration of XEOMIN® may potentiate systemic anticholinergic effects. The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.
USE IN PREGNANCY
There are no adequate data on the developmental risk associated with the use XEOMIN® in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
PEDIATRIC USE
Safety and effectiveness of XEOMIN® in patients less than 18 years of age have not been established.